Clinical Genetics Branch Eligibility Screening Survey

Part of paid clinical trials in Rockville, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT07005297
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • CFC Syndrome (CFCS)
  • Chordoma
  • Congenital Bone Marrow Failure Syndromes
  • Costello Syndrome
  • Fanconi Anemia
  • Legius Syndrome
  • Li-Fraumeni Syndrome
  • Melanoma
  • Pulmonary Blastoma
  • RASopathies

Eligibility Criteria

Sex
ALL
Age
1 Year - 99 Years
Healthy Volunteers
Not accepted

Study Details

Background: Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer in order to improve our understanding of cancer and to improve cancer care. There are currently 6 open clinical genetics studies at the CGB eligible for this screening process. * 02C0052: Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study (Cancer in Bone Marrow Failure) * 11C0255: Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome (Li Fraumeni Syndrome Study) * 11C0034: DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study (Pleuropulmonary Blastoma) * 02C0211: Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma (Melanoma-Prone Families) * 10CN188: Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-susceptibility Genes (Sporadic Chordoma Study) The following studies have their own study-specific screeners. If you are interested in these studies, please click the links below to fill out the relevant study screener: * 001109: Defining the Natural History of Squamous Cell Carcinoma in Fanconi anemia (SCC Screening in FA): https://service.cancer.gov/fanconi * 20C0107: Clinical, Genetic, and Epidemiologic Study of Children and Adults with RASopathies (RASopathies Study): https://service.cancer.gov/myras Objective: To find people to participate in active CGB cancer research studies. Eligibility: People of any age who meet the eligibility criteria for one of the open CGB cancer research studies. You can learn more about the CGB cancer research studies by clicking on the links to the study-specific websites above. This typically involves a personal or family history of certain cancers that are being studied by researchers at CGB. Design: Participants will fill out a screening questionnaire to determine if they are eligible to participate in one or more CGB clinical genetics studies. The survey asks about personal health history, including cancer; family history; and genetic testing results and takes 15 to 20 minutes. Each study has its own eligibility criteria. Survey respondents will select which study (or studies) that are interested in participating in, and the relevant study team(s) will review the screener to determine eligibility to participate in the study. Participants who are determined to be eligible for a study based on their screener will be contacted by the respective study team to learn more about the study and to consent to enroll in the study if they choose to do so. Participants who consent to enroll in a study may be asked to provide medical records; samples such as blood, saliva, or other tissues; and to participate in activities such as phone interviews or surveys. They may be invited for evaluations at the clinical center. Every study activity is voluntary. None of the studies provide treatments. Participants may be contacted to consider enrolling in future studies.

Key Dates

Start date
Jun 16, 2026
Status verified
Sep 2025
Primary completion
Jan 1, 2035
Completion
Jan 1, 2036

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Prospective Cohort
    Prospective Cohort

Primary Outcome Measure

Number of Eligible Participants Identified [ Time Frame: Duration of the protocol ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
National Cancer InstituteRockvilleMaryland20850
Sharon Savage, M.D.
[email protected]
240-276-7241

Find similar trials in Rockville, MD

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
National Cancer Institute· Rockville, MD

Related Studies